Lucid Diagnostics Business Summary

Lucid Diagnostics Inc. (LUCD) is a commercial-stage medical technology company specializing in the early detection of esophageal cancer and its precursor, Barrett’s Esophagus. The company generates revenue primarily through a fee-for-service model by processing its flagship EsoGuard Esophageal DNA Test, which is performed on cells collected via its proprietary EsoCheck non-invasive cell collection device. Its business segments are concentrated in diagnostic laboratory services and medical device sales, targeting the millions of patients with chronic gastroesophageal reflux disease (GERD). As of early 2026, Lucid is transitioning into a high-growth phase following a unanimous positive Medicare (MolDx) advisory consensus in late 2025, which significantly expanded its total addressable market. Its primary competitors include Interpace Biosciences, NeoGenomics, and Exact Sciences; however, Lucid maintains a unique market position as the provider of the only commercially available non-invasive alternative to traditional endoscopic screening for esophageal precancer. The company is led by Chairman and CEO Dr. Lishan Aklog, a Harvard-trained cardiac surgeon and prolific inventor who co-founded Lucid’s parent company, PAVmed Inc. The executive team includes President and COO Shaun M. O’Neil, who oversees commercial operations, and CFO Dennis M. McGrath. Technical leadership is provided by Chief Technology and Compliance Officer Dr. Brian J. DeGuzman, a cardiovascular surgeon, and Chief Scientific Officer Dr. Suman M. Verma, a molecular biologist instrumental in the commercial validation of the EsoGuard assay. Lucid’s strategic direction is further bolstered by Vice-Chairman Stanley N. Lapidus, a diagnostics pioneer who founded Exact Sciences and Cytyc Corp. The company’s board features prominent industry figures such as Sentara Health CEO Dennis Matheis and cardiac surgery pioneer Dr. James L. Cox. Major institutional backing is provided by PAVmed Inc., alongside significant positions held by The Vanguard Group, BlackRock, and Masters Capital Management.